166 related articles for article (PubMed ID: 11585680)
1. Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy.
Capuron L; Ravaud A; Gualde N; Bosmans E; Dantzer R; Maes M; Neveu PJ
Psychoneuroendocrinology; 2001 Nov; 26(8):797-808. PubMed ID: 11585680
[TBL] [Abstract][Full Text] [Related]
2. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy.
Capuron L; Ravaud A; Miller AH; Dantzer R
Brain Behav Immun; 2004 May; 18(3):205-13. PubMed ID: 15050647
[TBL] [Abstract][Full Text] [Related]
3. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy.
Capuron L; Ravaud A; Dantzer R
J Clin Oncol; 2000 May; 18(10):2143-51. PubMed ID: 10811680
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms.
Bonaccorso S; Puzella A; Marino V; Pasquini M; Biondi M; Artini M; Almerighi C; Levrero M; Egyed B; Bosmans E; Meltzer HY; Maes M
Psychiatry Res; 2001 Dec; 105(1-2):45-55. PubMed ID: 11740974
[TBL] [Abstract][Full Text] [Related]
5. Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy.
Maes M; Capuron L; Ravaud A; Gualde N; Bosmans E; Egyed B; Dantzer R; Neveu PJ
Neuropsychopharmacology; 2001 Feb; 24(2):130-40. PubMed ID: 11120395
[TBL] [Abstract][Full Text] [Related]
6. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
8. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.
Capuron L; Ravaud A; Neveu PJ; Miller AH; Maes M; Dantzer R
Mol Psychiatry; 2002; 7(5):468-73. PubMed ID: 12082564
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Eur Urol; 2002 Apr; 41(4):458-67; discussion 467-8. PubMed ID: 12074819
[TBL] [Abstract][Full Text] [Related]
10. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol.
Wichers MC; Kenis G; Koek GH; Robaeys G; Nicolson NA; Maes M
J Psychosom Res; 2007 Feb; 62(2):207-14. PubMed ID: 17270579
[TBL] [Abstract][Full Text] [Related]
11. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of cytokines and soluble cytokine receptors in patients with metastatic renal cell carcinoma or malignant melanoma receiving IL-2/interferon-alpha combination therapy.
Fosså SD; Aamdal S; Naume B; Gallati H
Acta Oncol; 1995; 34(5):599-603. PubMed ID: 7546824
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract][Full Text] [Related]
14. Associations between plasma cytokines and depressive mood in patients with breast cancer.
Kim SY; Kim JM; Kim SW; Shin IS; Park MH; Yoon JH; Choi C; Yoon JS
Int J Psychiatry Med; 2012; 43(1):1-17. PubMed ID: 22641927
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?
Kenis G; Prickaerts J; van Os J; Koek GH; Robaeys G; Steinbusch HW; Wichers M
Int J Neuropsychopharmacol; 2011 Mar; 14(2):247-53. PubMed ID: 20667172
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
17. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation.
Maes M; Bonaccorso S; Marino V; Puzella A; Pasquini M; Biondi M; Artini M; Almerighi C; Meltzer H
Mol Psychiatry; 2001 Jul; 6(4):475-80. PubMed ID: 11443537
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer.
Jayson GC; Middleton M; Lee SM; Ashcroft L; Thatcher N
Br J Cancer; 1998 Aug; 78(3):366-9. PubMed ID: 9703284
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
